Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the overall efficacy, and safety profile of the triple combination
therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV)
patients with chronic hepatitis C (HCV) genotype 1 who failed prior treatment with a protease
inhibitor (PI).
Phase:
Phase 3
Details
Lead Sponsor:
Debiopharm International SA
Treatments:
HIV Protease Inhibitors Peginterferon alfa-2a Protease Inhibitors Ribavirin